OMIC · Singular Genomics Systems, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $406.0K | $737.0K | $442.0K | - | $462.0K | $505.0K | $863.0K | - | - | - |
| Cost of Revenue | $707.0K | $915.0K | $861.0K | - | $0 | $0 | $807.0K | - | - | - |
| Gross Profit | ($301.0K) | ($178.0K) | ($419.0K) | - | ($65.0K) | $0 | $0 | - | - | - |
| R&D | $9.57M | $10.73M | $11.49M | - | $11.22M | $12.62M | $12.23M | - | $12.73M | $12.06M |
| SG&A | $8.20M | $11.90M | $14.94M | - | $13.25M | $14.89M | $13.20M | - | $11.96M | $6.20M |
| Total Operating Expenses | $17.77M | $22.63M | $26.43M | - | $24.47M | $27.51M | $25.43M | - | $24.69M | $24.24M |
| D&A | - | - | $1.02M | - | - | - | $793.0K | - | - | - |
| Operating Income | ($18.07M) | ($22.80M) | ($26.85M) | - | ($24.54M) | ($27.60M) | ($25.38M) | - | ($24.69M) | ($24.24M) |
| Interest Expense | $286.0K | $286.0K | $284.0K | - | $285.0K | $270.0K | $259.0K | - | $211.0K | $167.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($16.80M) | ($21.25M) | ($25.02M) | - | ($22.36M) | ($25.58M) | ($23.63M) | - | ($23.79M) | ($23.98M) |
| EPS - Basic | ($6.72) | ($8.57) | ($0.34) | - | ($0.31) | ($0.35) | ($0.31) | - | ($0.33) | ($0.34) |
| EPS - Diluted | ($6.72) | ($8.57) | ($0.34) | - | ($0.31) | ($0.35) | ($0.31) | - | ($0.25) | ($0.34) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.62M | $30.11M | $24.11M | $16.23M | $33.30M | $74.82M | $129.28M | $74.27M | $93.26M | $153.12M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $12.41M | $12.44M | $13.08M | $13.57M | $13.42M | $14.35M | $17.16M | $18.22M | $16.70M | $12.22M |
| Accounts Payable | $1.88M | $1.50M | $2.01M | $2.59M | $2.43M | $1.97M | $1.98M | $3.10M | $2.98M | $4.02M |
| Current Assets | $129.81M | $148.69M | $166.47M | $192.23M | $210.79M | $225.69M | $246.47M | $268.43M | $286.11M | $305.95M |
| Total Assets | $186.55M | $220.00M | $239.10M | $265.47M | $284.52M | $283.98M | $305.47M | $327.98M | $345.48M | $366.41M |
| Current Liabilities | $17.61M | $16.95M | $16.08M | $18.29M | $15.45M | $13.95M | $12.49M | $14.12M | $14.18M | $13.31M |
| Long-term Debt | $5.17M | $6.36M | $7.63M | $8.90M | $10.18M | $10.14M | $10.10M | $10.06M | $10.03M | $9.98M |
| Total Liabilities | $63.30M | $82.30M | $82.40M | $86.46M | $85.49M | $65.59M | $65.14M | $67.65M | $68.55M | $68.85M |
| Stockholders' Equity | $123.25M | $137.71M | $156.70M | $179.01M | $199.03M | $218.39M | $240.32M | $260.32M | $276.93M | $297.56M |
| Retained Earnings | ($400.67M) | ($383.87M) | ($362.62M) | ($337.60M) | ($314.35M) | ($291.99M) | ($266.41M) | ($242.78M) | ($221.67M) | ($197.88M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($23.70M) | - | - | - | ($17.93M) | - | - | - |
| Investing Cash Flow | - | - | $31.58M | - | - | - | $72.94M | - | - | - |
| Financing Cash Flow | - | - | $0 | - | - | - | $6.0K | - | - | - |
| CapEx | - | - | $25.0K | - | - | - | $162.0K | - | - | - |
| Free Cash Flow | - | - | ($23.73M) | - | - | - | ($18.10M) | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -74.1% | -24.2% | -94.8% | - | -14.1% | 0.0% | 0.0% | - | - | - |
| Operating margin | -4451.0% | -3094.2% | -6074.2% | - | -5311.5% | -5465.9% | -2940.7% | - | - | - |
| EBITDA margin | - | - | -5843.7% | - | - | - | -2848.8% | - | - | - |
| Net margin | -4136.7% | -2883.9% | -5661.5% | - | -4839.8% | -5065.0% | -2738.5% | - | - | - |
| Free cash flow margin | - | - | -5368.3% | - | - | - | -2096.9% | - | - | - |
| FCF / Net income | - | - | 0.95 | - | - | - | 0.77 | - | - | - |
| R&D / Revenue | 2356.7% | 1455.6% | 2600.5% | - | 2428.6% | 2499.8% | 1417.1% | - | - | - |
| SG&A / Revenue | 2020.2% | 1614.4% | 3379.0% | - | 2868.8% | 2947.9% | 1530.0% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.0% | -9.7% | -10.5% | - | -7.9% | -9.0% | -7.7% | - | -6.9% | -6.5% |
| Return on equity | -13.6% | -15.4% | -16.0% | - | -11.2% | -11.7% | -9.8% | - | -8.6% | -8.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.37 | 8.77 | 10.35 | 10.51 | 13.64 | 16.18 | 19.73 | 19.01 | 20.18 | 22.98 |
| Quick ratio | 6.67 | 8.04 | 9.54 | 9.77 | 12.77 | 15.15 | 18.36 | 17.72 | 19.00 | 22.07 |
| Cash ratio | 2.99 | 1.78 | 1.50 | 0.89 | 2.15 | 5.36 | 10.35 | 5.26 | 6.58 | 11.50 |
| Leverage | ||||||||||
| Debt / Equity | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 |
| Debt / Assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -63.2x | -79.7x | -94.5x | - | -86.1x | -102.2x | -98.0x | - | -117.0x | -145.2x |
| Equity multiplier | 1.51 | 1.60 | 1.53 | 1.48 | 1.43 | 1.30 | 1.27 | 1.26 | 1.25 | 1.23 |
| Liabilities / Assets | 0.34 | 0.37 | 0.34 | 0.33 | 0.30 | 0.23 | 0.21 | 0.21 | 0.20 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | - |
| Inventory turnover | 0.06 | 0.07 | 0.07 | - | 0.00 | 0.00 | 0.05 | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 6407d | 4963d | 5545d | - | - | - | 7761d | - | - | - |
| Days payable outstanding | 972d | 598d | 853d | - | - | - | 894d | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -12.1% | 45.9% | -48.8% | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -363.1% | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 26.4% | 17.4% | -5.8% | - | 0.6% | -13.9% | -15.2% | - | -41.4% | -74.6% |
| Net income growth (YoY) | 24.9% | 16.9% | -5.9% | - | 6.0% | -6.7% | -7.4% | - | -35.1% | -250.3% |
| EPS growth (YoY) | -2067.7% | -2348.6% | -9.7% | - | -24.0% | -2.9% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -31.1% | - | - | - | -86.7% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -38.1% | -36.9% | -34.8% | -31.2% | -28.1% | -26.6% | -24.3% | -22.6% | -21.3% | - |
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Singular Genomics Systems against the 5 most active filers in the same SIC group.